Clinical trials: Patients With Diabetes.
Diabetic Ketoacidosis
REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis
A number of scientific papers have been published on the efficacy and safety of adding REAMBERIN® (meglumin sodium succinate), a 1.5% infusion solution, to standard therapy for patients with diabetic ketoacidosis (DKA), which…
- Trial name
- NCT06955416
- Testing
- Reamberin
- Where
- 3 sites in Russia
- Volunteers
- 312 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Diabetes Type 1
Glycemic Control and Quality of Life Evolution for Patients With T1D Using the myLoop Powered by CamAPS FX System in Combination With FreeStyle Libre 3 / 3 Plus Sensors in France
The goal of this observational study is to learn how glucose control changes over one year in people with type 1 diabetes who use the myLoop with CamAPS FX and Freestyle Libre 3 or FreeStyle Libre 3 Plus during usual care in…
- Trial name
- NCT07835685
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 220 people
- Sponsor
- mylife Diabetes Care AG
Type 2 Diabetes Mellitus
A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment
The purpose of this study is to compare insulin peglispro (LY2605541) to insulin glargine in Asian insulin naïve participants who have been treated with oral anti hyperglycemia medications.
- Trial name
- NCT01894568
- Testing
- Insulin Peglispro, Insulin Glargine, Oral Antihyperglycemic Medications (OAMs)
- Where
- 31 sites in Japan, South Korea and 1 more
- Volunteers
- 388 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes.
- Trial name
- NCT00263276
- Testing
- dapagliflozin, metformin
- Where
- 144 sites in United States, Canada and 2 more
- Volunteers
- 389 people
- Sponsor
- AstraZeneca
Type-1 Diabetes
Safety and Feasibility Study of the Eddii Mobile Application
The study is designed to measure the safety and feasibility of the Eddii mobile app for children living with Type-1 diabetes and using a CGM (Continuous Glucose monitor).
- Trial name
- NCT05205876
- Testing
- Eddii mobile application
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Eddii, Inc.
Heart Failure
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.
The purpose of this study is to determine the effects of candesartan, once daily (QD), on the N-terminal pro-B-type Natriuretic Peptide laboratory marker in subjects with symptomatic heart failure with diastolic dysfunction.
- Trial name
- NCT00775840
- Testing
- Candesartan
- Where
- 37 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)
Purpose of this study is to evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination with GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic…
- Trial name
- NCT02291874
- Testing
- Ipragliflozin
- Where
- 6 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Astellas Pharma Inc
Diabetes Mellitus Type 2
A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease
A single center, double-blind, placebo-controlled, randomized, crossover, phase II study to assess the effect of aleglitazar on cardiac energetics and function in patients with uncomplicated type 2 diabetes mellitus and no…
- Trial name
- NCT01680978
- Testing
- aleglitazar
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus
Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose
Whether a combination of three therapies - metformin and a sulfonylurea plus Exubera, an investigational drug, controls your diabetes at least as much as a triple combination therapy of metformin and a sulfonylurea plus Avandia…
- Trial name
- NCT00150410
- Testing
- Inhaled insulin
- Where
- 119 sites in United States, Australia and 3 more
- Volunteers
- 626 people
- Sponsor
- Pfizer
Pharmacological Action
Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients
Sitagliptin, through its effects on sensitizing alpha-cell sensitivity to glucose, can initiate counter-regulatory glucagon responses at higher glycemic thresholds, thus reducing the number of clinically apparent hypoglycemic…
- Trial name
- NCT03359590
- Testing
- Sitagliptin 100 mg
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?
This clinical, prospective, randomized, multi-center study determined if the use of an insulin bolus advisor improves glycemic control as measured by a change in HbA1c in patients failing multiple daily injection/intensified…
- Trial name
- ABACUS (NCT01460446)
- Testing
- Aviva Expert blood glucose meter, Aviva Nano blood glucose meter
- Where
- 33 sites in Germany, United Kingdom
- Volunteers
- 218 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Mellitus
Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes
Primary Objective: To evaluate the decrease of Hb A1c ≥ 1% after 6 month treatment in patients with Type 2 Diabetes Mellitus (T2DM) uncontrolled on Oral Antidiabetics (OADs) Secondary Objectives: To evaluate the percentage of…
- Trial name
- SPIRIT (NCT01630369)
- Testing
- insulin human (HR1799)
- Where
- Ukraine
- Volunteers
- 552 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type II
GOLO Open-Label Pilot 1
The objective of this open-label pilot study is to evaluate the effect of the commercially available GOLO for Life (GFL) weight management program on body weight in a type 2 diabetic patient population after approximately 3…
- Trial name
- NCT03478202
- Testing
- GOLO RELEASE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Golo
Diabetes Mellitus, Type 2
Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide
The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently…
- Trial name
- NCT00279045
- Testing
- Rosiglitazone, glyburide, metformin
- Where
- 490 sites in United States, Austria and 15 more
- Volunteers
- 4,426 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)
To compare efficacy and safety of initial combination therapy of Gemigliptin versus Sitagliptin or Glimepiride with Metformin on Glucose Variability(MAGE, Glucose SD) in Patients With Type 2 Diabetes Mellitus.
- Trial name
- STABLE (NCT01890629)
- Testing
- Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- LG Life Sciences
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given over 12 weeks in drug naive or previously treated type 2 diabetic patients…
- Trial name
- NCT01087502
- Testing
- Glimepiride, Linagliptin
- Where
- 52 sites in United States, Australia and 7 more
- Volunteers
- 241 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
Empagliflozin vs. Dipeptidyl Peptidase 4 (DPP-4) Inhibitors and Glucagon-like Peptide-1 Receptor Agonists (GLP-1-RA) Cost of Care Study: a German claims data analysis
- Trial name
- NCT04295005
- Testing
- Empagliflozin, DPP-4i, GLP-1-RA
- Where
- Germany
- Volunteers
- 24,500 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"
The purpose of this survey is to evaluate the safety and efficacy of long-term use of alogliptin tablets (Nesina Tablets) in type 2 diabetic patients who have had an inadequate response to hypoglycemic agents (e.g., insulin…
- Trial name
- NCT02221284
- Testing
- Alogliptin
- Where
- 2 sites in Japan
- Volunteers
- 964 people
- Sponsor
- Takeda
Diabetes Mellitus Type 2
A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.
This 2 arm study will compare the safety, tolerability and efficacy of aleglitazar and Actos in patients with type 2 diabetes and symptomatic NYHA class II heart failure.
- Trial name
- NCT00461058
- Testing
- Actos, aleglitazar
- Where
- 45 sites in United States, Israel and 4 more
- Volunteers
- 14 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Digital Diabetes Remission Trial
This is a multicentre, open-label Randomised Controlled Trial run in the United Kingdom. The main aims are to assess whether the Habitual Remission Programme (digital therapeutics + 12-week 800kcal/day low-energy diet, delivered…
- Trial name
- DIGEST (NCT05647226)
- Testing
- Digital therapeutic and intensive lifestyle programme, Standard of care
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Habitual Health Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.